- Home
- IRMD vs PHAR Comparison
IRMD vs PHAR Comparison
Compare IRMD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- PHAR
- Stock Information
- Founded
- IRMD 1992
- PHAR 1988
- Country
- IRMD United States
- PHAR Netherlands
- Employees
- IRMD N/A
- PHAR N/A
- Industry
- IRMD Medical/Dental Instruments
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- PHAR Health Care
- Exchange
- IRMD Nasdaq
- PHAR Nasdaq
- Market Cap
- IRMD 766.5M
- PHAR 618.3M
- IPO Year
- IRMD 2014
- PHAR N/A
- Fundamental
- Price
- IRMD $62.16
- PHAR $8.42
- Analyst Decision
- IRMD Strong Buy
- PHAR Strong Buy
- Analyst Count
- IRMD 1
- PHAR 3
- Target Price
- IRMD $60.00
- PHAR $27.00
- AVG Volume (30 Days)
- IRMD 36.9K
- PHAR 5.6K
- Earning Date
- IRMD 02-13-2025
- PHAR 03-13-2025
- Dividend Yield
- IRMD 0.98%
- PHAR N/A
- EPS Growth
- IRMD 13.16
- PHAR N/A
- EPS
- IRMD 1.46
- PHAR N/A
- Revenue
- IRMD $71,305,130.00
- PHAR $285,745,000.00
- Revenue This Year
- IRMD $13.60
- PHAR $20.08
- Revenue Next Year
- IRMD $10.46
- PHAR $9.22
- P/E Ratio
- IRMD $41.82
- PHAR N/A
- Revenue Growth
- IRMD 13.23
- PHAR 30.64
- 52 Week Low
- IRMD $40.18
- PHAR $6.65
- 52 Week High
- IRMD $61.25
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- IRMD 67.60
- PHAR 40.05
- Support Level
- IRMD $57.96
- PHAR $7.95
- Resistance Level
- IRMD $61.09
- PHAR $9.35
- Average True Range (ATR)
- IRMD 1.63
- PHAR 0.52
- MACD
- IRMD 0.04
- PHAR -0.16
- Stochastic Oscillator
- IRMD 88.56
- PHAR 22.76
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.